

Non-Financial Information

Name of Organization:
VIVA FOUNDATION FOR CHILDREN WITH CANCER

Registered Address:
8 Sinaran Drive
#03-01 VIVA-CCF Hub
Singapore 307470

Contact Information:
Telephone No.: 65 6694 3370
Fax. No.: 65 6694 3372
Email Address: admin@viva.sg
Website Address: www.viva.sg

Directory

Unique Entity Number (UEN)	:	200601578E
Charity Registration Number	:	01961
Current IPC Effective Period	:	15 May 2013 – 14 May 2016
HEF Registration Number	:	HEF 0105/G
Bankers	:	Citibank Singapore Ltd Oversea-Chinese Banking Corporation Ltd
Auditors	:	Moore Stephens LLP

Board of Directors

<u>Name</u>	<u>Position</u>	<u>Date of Appointment</u>
Foo-Yo Mie Yoen Theresa	Chairman	6 February 2006
Leong Lai Peng	Director/Secretary	6 February 2006
Christina Ong @Christina Fu	Director	6 February 2006
Kwee Liong Keng	Director	6 February 2006
Koh Seow Chuan	Director	20 October 2006
Lee Ming San	Director	20 October 2006
Kuok Oon Kwong	Director	9 November 2007
Mary Ann Wai Sheng Tsao	Director	21 August 2008
Tan Wah Yeow	Director	1 September 2010

Mission

Saving lives of children with cancer through excellence in medical care, research and education.

VIVA Foundation for Children with Cancer (“Viva”) was set up on 6 February 2006 and registered with the Accounting and Corporate Regulatory Authority (ACRA) as a Company Limited by Guarantee. VIVA was also registered under the Charities Act on 25 April 2006. It has Institution of Public Character (IPC) status and has been a member of Health Endowment Fund since 8 May 2006.

Objectives

The goal of VIVA Foundation is to improve the survival rate and cure of children with cancer, especially childhood leukaemia, in Singapore and the region. Viva Foundation seeks to achieve this by facilitating partnerships between St Jude Children’s Research Hospital (“St Jude”) in Tennessee, USA, the National University Hospital in Singapore (“NUH”) and the National University of Singapore (“NUS”) so there is robust research, knowledge-transfer and cross-learning.

Viva Programs

Viva-University Children’s Cancer Centre (VUC³)

To date, VIVA has established a world-class clinical research and treatment centre at NUH. Known as the VIVA-University Children Cancer Centre (VUC³), the Centre works closely with St Jude to promote translational, clinical research and treatment of childhood cancer. It also advances the training of doctors and nurses from the National University Health System (“NUHS”), KK Women’s and Children’s Hospital (“KKWCH”) and the region, such that research can be translated into reality. It is hoped that the VUC³ will become a world-class centre for the treatment of childhood cancers by adopting state-of-the-art medical practices in terms of organization, clinical treatment, care and research.

Since its official opening in 2008, VUC³ has grown rapidly and its expanding reputation can be seen by the increased numbers of complex referral cases and participation in clinical research. In 2013, VUC³ expanded and is now housed across two NUH spaces - in ward 8B, Kent Ridge Wing and in Level 9 of the NUH Medical Centre. It boasts state-of-the-art transplant facilities, complete with in-patient wards and out-patient consultation, as well as day therapy areas so every child with cancer can receive care in a world-class holistic treatment environment.

The number of patient cases seen at the VUC³ in 2013 has been summarized over the following pages:




Table 1: Total Number of Cases versus Oncology Cases 2006 – 2013

Source: VIVA-University Children's Cancer Centre




Table 2: Patient Admissions to VUC³ 2006 - 2013

Source: VIVA-University Children's Cancer Centre




Table 3: Blood and Marrow Transplants 2006 – 2013

Source: VIVA-University Children's Cancer Centre

Clinical Research Program

One of Viva's foremost aims is to improve cure rates for childhood cancers through fostering research and enabling novel therapies through the strategic setting-up of critical facilities. In 2012 and 2013, VIVA has been raising funds for an unrivalled leukaemia research and diagnostics laboratory in Asia. The facility will combine molecular, flow-cytometry and cellular therapies under one roof and will include tissue banking. The project launch is planned for end 2014/early 2015, and it will cover two areas of focused clinical research:

- **Minimal Residual Disease:** New equipment and facilities will allow Viva to establish state-of-art trials in treating childhood acute leukaemia through **molecular and flow-based Minimal Residual Disease (MRD)** which will allow the doctors to accurately diagnose predict the risk of relapse in almost every child with leukaemia.
- **Cellular-Based Therapy:** In Singapore, our small families limit the chances of finding a matched donor for stem cell transplantation; Viva will thus enhance local capability of alternative stem cell transplantation using matched unrelated donors and haploidentical transplantation from parents. Through this program, we hope more children who lack a matched sibling donor can be offered a chance of cure.

In 2011, Viva Foundation started funding the **St. Jude-Acute Myeloid Leukaemia (AML) 2008 Study** in VUC³ which incorporates many new exciting therapies like haploidentical natural killer cells to eradicate residual leukaemia cells. To date, 4 patients have enrolled and received treatment on this trial.

St Jude-Viva Forum in Paediatric Oncology

This annual forum is the primary platform for top doctors and scientists from all over the world to exchange information and collaborate on translational clinical research in childhood cancer. Interaction between participants is extended through Pre-Forum workshops focused on issues uniquely relevant to participants from countries in the region. The 7th annual St Jude-Viva Forum in Paediatric Oncology was held at the Shangri-La Hotel, Singapore from 8th to 9th March 2013. The presentations at the Forum were from 14 world experts from the USA, Germany, The Netherlands and Singapore. The total attendance at the Forum was 237, with delegates from Australia, Brazil, Brunei Darussalam, Cambodia, China, Hong Kong, India, Indonesia, Japan, Kingdom of Bahrain, Malaysia, Myanmar, New Zealand, Philippines, Saudi Arabia, Singapore, South Korea, Sri Lanka, Taiwan, Thailand and Vietnam.

Working Groups and Pre-Forum Workshop

On top of the St Jude-Viva Forum itself, there are three other important ongoing initiatives. These are the Viva-Asia Acute Leukaemia (VAWGM), the Viva-Asia Bone Marrow Transplant (VABMT) Working Groups and the Pre-Forum Workshop.

- The VAWGM Working Group which last met on 10 March 2013, encouraged clinicians, scientists and researchers to meet and develop ideas to standardise, collaborate and support each other. Eventually the hope is that VAWGM is able to coordinate common questions and indications for research, training and standards, translating care of childhood leukaemia therapy to Asia. The total attendance was 15 from Australia, Hong Kong, Japan, Singapore and Taiwan. Leaders from the major Asian cooperative groups were invited to look at their data and present on the selected

topics. The meeting included a combined session with the VABMT Meeting with a presentation by Dr Dario Campana and Dr Tan Poh-Lin on “Advances in NK Cell Therapy in Singapore”. The key outcomes of the VAWG Meeting were progress towards Acute Promyelocytic Leukaemia (APL) and arsenic protocols.

- The VABMT is a platform to learn from each other’s centres and the working group has been exploring and implementing opportunities to work together in research and strategic planning for paediatric bone marrow transplant in the region. The VABMT Working Group last met in Singapore on 10 March 2013. The meeting was chaired by Dr Godfrey Chan from Hong Kong and was attended by 31 members representing Japan, Hong Kong, Peoples’ Republic of China, Philippines, Singapore, Thailand and the USA. The full day meeting was a review of 12 months of work in the various subcommittees formed at the first meeting and this consisted of:
 1. Supportive care
 2. Clinical transplant protocol
 3. Electronic database
 4. Research
 5. Nursing and supportive staff
 6. Membership and accreditation

The key outcomes of the VABMT Consortium were:

1. Introduction of new members and updates on applications under review.
 2. Review of pending publications – Bone Marrow Transplant (BMT) Survey and Severe Aplastic Anaemia and Thalassemia. (Note: The paper on Aplastic Anaemia has since been accepted by Br J Haematol)
 3. Education and Supportive Care Subcommittees merged and more than 10 supportive guidelines have been drafted.
 4. Re-establishment of the Laboratory Support Subcommittee
 5. Aim for prospective clinical trial to start this year, the conditioning regimen for high risk or relapsed Acute Lymphoid Leukaemia (ALL) has been finalized.
- The Pre-Forum Workshop, held on 6th and 7th March 2013, allowed for clinicians from developing countries to meet and discuss the current status of paediatric oncology programs at their centres and common problems faced within the group. A panel of regional and international experts are represented in the faculty and as speakers. The Pre-Forum Workshop Organizing Committee consisted of Dr Ana Patricia Alcasabas and Dr Quah, NUHS; Dr Mae Dolendo, Southern Philippines Medical Centre; Dr Raul Ribeiro, St Jude Children’s Research Hospital (SJCRH) and Dr Anjo Veerman, Vrije University, The Netherlands. For 2013, the title of the Pre-Forum Workshop was **“Cancer Treatment in Developing Countries: Focus on Southeast Asia”**. The objectives were to discuss about the current status of paediatric oncology treatment in the region plus updates on the health care initiatives to tackle common problems such as lack of palliative care, late presentation of tumours such as retinoblastoma and establishment of a cancer registry; as well as to discuss leukaemia and solid tumour cases in a multi-disciplinary meeting format. The total attendance was 55, with representatives from Cambodia, India, Indonesia, Japan, Malaysia, Myanmar, Philippines, Sri Lanka, Singapore, Thailand and Vietnam.

All these meetings collectively sought to enhance regional collaboration and provide the opportunity to learn from each other’s experience such that there is a levelling-up in childhood leukaemia cure rates. For the Viva-Asia Working Groups, leaders from the major Asian cooperative groups were also invited to look at their data and had it presented within a small group meeting of Asian leaders during the meeting. For the Pre-Forum, the group agreed to undertake common or joint projects between regions and hospitals. Such opportunities encourage closer collaboration and transform the St Jude-Viva Forum from a passive learning annual forum to an active collaborative year-round, borderless dialogue.

Viva-CCF Hub at Novena Specialist Centre

Since 2011, Viva Foundation has been running the Viva-CCF Hub on a cost-recovery basis. Today, it brings together the head offices of Viva Foundation, Children's Cancer Foundation (CCF), Singapore Cord Blood Bank (SCBB) and the Bone Marrow Transplant Program (BMTP) under one roof to offer the best in childhood cancer care and cure. Occupying the 3rd level of Novena Specialist Centre, the premises is a designated civic and community space which includes a Place for Academic Learning and Support (or PALS) School, operated by the CCF, for children with or recovering from cancer to still be able to attend school in an infectious disease controlled environment.

Financial Information

Viva Foundation received resources amounting to S\$617,152 in 2013.

A total expense for 2013 was S\$1,401,267. Nearly all of the expenses were related to the donated premises which we are now occupying, e.g. non-recoverable GST, depreciation and maintenance fees.

As a result, Viva recorded a net deficit of S\$784,115 for 2013.

INCOME & EXPENDITURE	2011 '000	2012 '000	2013 '000	% Increase/(Decrease) [2013 vs 2012]
Income				
Donations in Cash				
Tax-Deductible	2,022	888	292	-67%
Non Tax-Deductible	-	14	127	784%
Donations in Kind				
Tax-Deductible	24,100	-	-	0%
Non Tax-Deductible	-	-	-	
Grants	10	-	-	0%
Sponsorships	-	-	-	
Investment Income	5	6	6	-2%
Investment Gains	-	-	-	
Programme Fees & other receipts	73	141	113	-19%
Others	-	-	78	
Total Income	26,210	1,049	617	-41%
Expenses				
Direct Fund-raising Expenses	-	-	-	0%
Charitable Activities Expenses				
Local	1	390	592	52%
Overseas	-	-	-	
Other Operating & Admin Expenses	1,644	660	809	23%
Others				
Total Expenditure	1,645	1,050	1,401	34%
Surplus / (Deficit)	24,565	(0)	(784)	397302%

BALANCE SHEET	2011 '000	2012 '000	2013 '000	% Increase/(Decrease) [2013 vs 2012]
Assets				
Land and Buildings	23,739	23,257	22,775	-2%
Other Tangible Assets	1	444	403	-9%
Investments	-	-	-	
Inventories	-	-	-	
Accounts Receivables & prepayments	10	579	134	-77%
Cash & Deposit	4,578	4,090	4,767	17%
Others				
Total Assets	28,327	28,369	28,079	-1%
Funds				
Unrestricted	28,310	28,310	27,526	-2.8%
Restricted	-	-	-	
Endowment Fund	-	-	-	
Total Funds	28,310	28,310	27,526	-2.8%
Liabilities				
Long-Term Liabilities				
Current Liabilities	16	59	553	833%
Total Liabilities	16	59	553	833%
Total Funds and Liabilities	28,327	28,369	28,079	-1%

OTHER INFORMATION	2011	2012	2013	% Increase/(Decrease) [2013 vs 2012]
Donations/Grants and Sponsorships given to other Charities	180,000	-	250,000 ¹	
No. of Employees	1	2	2	0%
Total Employee Costs	52,263	118,211	184,679	56%
Total Related Party Transactions ²	-	-	-	
Fund-raising efficiency ³	0%	19%	0%	100%
Ratio of reserves to annual operating expenditure ⁴	17	27	20	-27%

Footnotes:

1. In 2013, Viva received a donation amounting to \$250,000 from Singapore Ireland Fund as a contribution towards PALS (Place for Academic Learning and Support) run by Children's Cancer Foundation at the Hub.
2. Related Party Transactions refer to transactions between the IPC and another person where either person could have influence over the other. For example, if a board member of an IPC is related to a certain supplier of services for the IPC, the value of the transactions should be disclosed. Refer to the Financial Reporting Standards for the full definition of Related Party Transactions.
3. Fund-raising Efficiency. This is expressed in the ratio of A to B, where A refers to Direct Fund-raising Expenses and sponsorships relating to fund-raising (where receipts have been issued by sponsors); and B refers to total donations received from fund-raising and sponsorships relating to fund-raising (where receipts have been issued by sponsors).
4. Ratio of reserves to annual operating expenditure. This is expressed in the ratio of C to D, where C refers to Unrestricted Funds; and D refers to Charitable Activities Expenses and Other Operating and Administration Expenses.